CTLA4 and prostate carcinoma: As described above, the GVAX cellular vaccine was evaluated alone and in combination with anti-CTLA-4 blocking antibodies in the TRAMP murine model of prostate cancer, and it demonstrated antitumor activity only with the combination treatment [22].